Provided herein are compounds and pharmaceutical compositions comprising said compounds that are useful for treating cancers. Specific cancers include those that are mediated by YAP/TAZ or those that are modulated by the interaction between YAP/TAZ and TEAD.

In one aspect, compounds of Formula A, or a pharmaceutically acceptable salt thereof, are featured, or a pharmaceutically acceptable salt thereof, wherein the variables shown in Formula A can be as defined anywhere herein. ##STR00001##

In one aspect, compounds of Formula A, or a pharmaceutically acceptable salt thereof, are featured, or a pharmaceutically acceptable salt thereof, wherein the variables shown in Formula A can be as defined anywhere herein. ##STR00001##

A class of water lean, organic solvents that can bind with various acid gasses to form acid gas bound molecules having a high degree of intramolecular hydrogen bonding which enables their use as regenerable solvents for acid gas capture. Unlike the other devices described in the prior art, the present invention takes advantage of shortened distances between the portions of the molecule that form hydrogen bonds within the structures when loaded with an acid gas so as to create a molecule with a higher internal bonding affinity and a reduced proclivity for agglomeration with other molecules.

In one aspect, compounds of Formula A, or a pharmaceutically acceptable salt thereof, wherein the variables shown in Formula A can be as defined anywhere herein.

##STR00001##

In one aspect, compounds of Formula A, or a pharmaceutically acceptable salt thereof, wherein the variables shown in Formula A can be as defined anywhere herein.

##STR00001##

A method of imparting to, or modifying in, a comestible product, umami taste, including the addition to a comestible product base of at least one compound of formula (I) ##STR00001##
wherein one of X.sub.1, X.sub.2, or X.sub.3 is selected from the group consisting of S, N and O and the remaining two are CH.sub.2; and A is selected from ##STR00002##
in which R.sub.1, R.sub.2, R.sub.3, R.sub.4 R.sub.5, R.sub.6 are independently selected from the group consisting of H, methyl, ethyl, propyl, OH, OMe, OEt, COOH, COOR.sub.7, in which R.sub.7 is selected from linear or branched C.sub.1-C.sub.7 alkyl, and CONR.sub.8R.sub.9, in which R.sub.8 and R.sub.9 are independently selected from hydrogen and straight or branched C.sub.1-C.sub.4 alkyl; or any two adjacent substituents R.sub.2-R.sub.6 together form a ring of 5 or 6 members; and n is 1 or 0.

A method of imparting to, or modifying in, a comestible product, umami taste, including the addition to a comestible product base of at least one compound of formula (I) ##STR00001##
wherein one of X.sub.1, X.sub.2, or X.sub.3 is selected from the group consisting of S, N and O and the remaining two are CH.sub.2; and A is selected from ##STR00002##
in which R.sub.1, R.sub.2, R.sub.3, R.sub.4 R.sub.5, R.sub.6 are independently selected from the group consisting of H, methyl, ethyl, propyl, OH, OMe, OEt, COOH, COOR.sub.7, in which R.sub.7 is selected from linear or branched C.sub.1-C.sub.7 alkyl, and CONR.sub.8R.sub.9, in which R.sub.8 and R.sub.9 are independently selected from hydrogen and straight or branched C.sub.1-C.sub.4 alkyl; or any two adjacent substituents R.sub.2-R.sub.6 together form a ring of 5 or 6 members; and n is 1 or 0.

A class of water lean, organic solvents that can bind with various acid gasses to form acid gas bound molecules having a high degree of intramolecular hydrogen bonding which enables their use as regenerable solvents for acid gas capture. Unlike the other devices described in the prior art, the present invention takes advantage of shortened distances between the portions of the molecule that form hydrogen bonds within the structures when loaded with an acid gas so as to create a molecule with a higher internal bonding affinity and a reduced proclivity for agglomeration with other molecules.

Prodrugs of pharmacologically active 1,2,4-triaminobenzene derivatives of the General Formula (I); or pharmaceutically acceptable salts thereof, where the symbols R.sup.1, R.sup.2, R.sup.3, R.sup.4, R.sup.5 and R.sup.6a, R.sup.6b, and R.sup.6c and where the symbol Z are defined. Methods for the synthesis, purification, testing and use as prodrugs of pharmacologically-active agents at Kv7 ion channels are provided.

##STR00001##